Translational Aspects of Cardiovascular Biology From Bench to Bedside
This reprint, edited by Prof. Gaetano Santulli, MD, PhD, collects the most up-to-date peer-reviewed scientific papers dealing with cardiovascular medicine, from basic science to pre-clinical and clinical investigations, highlighting the fundamental importance of translational medicine in the challen...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_100829 | ||
| 005 | 20230623 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20230623s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-7574-2 | ||
| 020 | |a 9783036575759 | ||
| 020 | |a 9783036575742 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-7574-2 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a MJD |2 bicssc | |
| 100 | 1 | |a Santulli, Gaetano |4 edt | |
| 700 | 1 | |a Santulli, Gaetano |4 oth | |
| 245 | 1 | 0 | |a Translational Aspects of Cardiovascular Biology |b From Bench to Bedside |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (240 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This reprint, edited by Prof. Gaetano Santulli, MD, PhD, collects the most up-to-date peer-reviewed scientific papers dealing with cardiovascular medicine, from basic science to pre-clinical and clinical investigations, highlighting the fundamental importance of translational medicine in the challenging quest for new therapies to cure cardiovascular disease. Indeed, cardiovascular disease is the leading cause of death worldwide, and the search for novel mechanisms and therapeutics is desperately needed. Therefore, both basic and translational studies in the cardiovascular field represent a paramount strategy to identify novel therapeutic targets and improve the quality of life of patients with cardiovascular disorders. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Cardiovascular medicine |2 bicssc | |
| 653 | |a cardiovascular disease | ||
| 653 | |a vaccine | ||
| 653 | |a clinical trials | ||
| 653 | |a translational medicine | ||
| 653 | |a atherosclerosis | ||
| 653 | |a oxLDL | ||
| 653 | |a phosphorylcholine | ||
| 653 | |a RBP-4 | ||
| 653 | |a insulin resistance | ||
| 653 | |a severity of CAD | ||
| 653 | |a T2D | ||
| 653 | |a atherosclerotic CAD | ||
| 653 | |a endothelial dysfunction | ||
| 653 | |a hypoxia | ||
| 653 | |a HIF-1α | ||
| 653 | |a mitochondria | ||
| 653 | |a oxidative stress | ||
| 653 | |a inflammation | ||
| 653 | |a cardiovascular diseases | ||
| 653 | |a cancer | ||
| 653 | |a therapeutic target | ||
| 653 | |a extracellular NAD+ metabolism | ||
| 653 | |a extracellular NMN metabolism | ||
| 653 | |a vascular endothelial cells | ||
| 653 | |a CD38 | ||
| 653 | |a CD73 | ||
| 653 | |a myocardial infarction | ||
| 653 | |a neuregulin | ||
| 653 | |a glial growth factor 2 | ||
| 653 | |a pre-clinical therapy | ||
| 653 | |a skeletal muscle | ||
| 653 | |a gene expression | ||
| 653 | |a RNA sequencing | ||
| 653 | |a inflammatory bowel disease | ||
| 653 | |a limb ischemia | ||
| 653 | |a endothelial function | ||
| 653 | |a ROS | ||
| 653 | |a acute myocardial infarction | ||
| 653 | |a diabetes | ||
| 653 | |a lactic acid | ||
| 653 | |a carbonic anhydrase | ||
| 653 | |a CD34 | ||
| 653 | |a endothelial cells | ||
| 653 | |a ERG | ||
| 653 | |a hypothermic oxygenated perfusion | ||
| 653 | |a liver transplantation | ||
| 653 | |a machine perfusion | ||
| 653 | |a nestin | ||
| 653 | |a VEGFR | ||
| 653 | |a IDH1 | ||
| 653 | |a foam cell | ||
| 653 | |a macrophage | ||
| 653 | |a ferroptosis | ||
| 653 | |a NRF2 | ||
| 653 | |a atrial fibrillation | ||
| 653 | |a obesity | ||
| 653 | |a immune infiltration | ||
| 653 | |a biomarkers | ||
| 653 | |a cardiac fibrosis | ||
| 653 | |a lncRNAs | ||
| 653 | |a TGF-β | ||
| 653 | |a ECMs | ||
| 653 | |a exosome | ||
| 653 | |a red blood cells | ||
| 653 | |a chemotherapy | ||
| 653 | |a anemia | ||
| 653 | |a microcirculation | ||
| 653 | |a laser diffraction | ||
| 653 | |a osmotic fragility test | ||
| 653 | |a microfluidics | ||
| 653 | |a valvular heart disease | ||
| 653 | |a degenerative aortic valve stenosis | ||
| 653 | |a irisin | ||
| 653 | |a periostin | ||
| 653 | |a osteoglycin | ||
| 653 | |a IL-18 | ||
| 653 | |a HMGB-1 | ||
| 653 | |a PCSK9 | ||
| 653 | |a blood-brain barrier | ||
| 653 | |a blood pressure | ||
| 653 | |a cerebrovascular disease | ||
| 653 | |a hBMECs | ||
| 653 | |a hypertension | ||
| 653 | |a HUVEC | ||
| 653 | |a microRNA | ||
| 653 | |a miRNA | ||
| 653 | |a miR-4432-3p | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/7292 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/100829 |7 0 |z DOAB: description of the publication |